Abstract:Kentaro Nakayama 1 , Sultana Razia 2 , Tomoka Ishibashi 1 , Satoru Kyo 3 1 Department of Obstetrics and Gynecology, Nagoya City University East Medical Center, Nagoya, Japan; 2 Department of Legal Medicine, Shimane University School of Medicine, Izumo, Japan; 3 Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan Comment on: Manning-Geist B, Gordhandas S, Liu YL, et al . MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. Clin Cancer Res 2022;28:4456-65. Keywords: Genetic alterations; low-grade serous ovarian carcinoma (LGSOC); MAPK pathway; molecular targeted therapy; overall survival (OS) Submitted Jul 07, 2023. Accepted for publication Dec 14, 2023. Published online Jan 25, 2024. doi: 10.21037/tcr-23-1161 Epithelial ovarian cancer (EOC) is responsible for more than 14,070 mortalities annually worldwide, making it the third most lethal malignancy affecting the female reproductive tract (1). Despite the significant advances in early diagnostic techniques, surgical techniques, and adjuvant therapy for ovarian cancer, the prognosis has remained unchanged for over 50 years. The significant postoperative prognostic factors include age, disease stage, performance status, histological subtype, tumor grade, and the extent of residual tumors (2). Among them, recognizing the histological subtypes is crucial for developing new treatment approaches due to their distinct molecular profiles. Recently, clinical, pathological, and molecular data have suggested that EOC can be broadly categorized into two subgroups as follows: types I and II (3). High-grade serous carcinomas (HGSOCs) are predominantly classified as type II tumors, representing the most common type of epithelial carcinoma, which is characterized by aggressive behaviors. Type I tumors include low-grade serous carcinoma (LGSOCs) and endometrioid, mucinous, and clear cell carcinomas. LGSOCs are relatively rare, typically diagnosed in younger women, and account for <5% of all ovarian carcinoma cases. The average age at diagnosis for LGSOCs is 55.5 years, which is significantly lower than the average age of 62.6 years for HGSOCs (4). A median age of 45 years has also been reported in several publications. LGSOCs can affect women of all ages, with reported cases occurring between the ages of nineteen and 79 years. They are believed to originate from serous cystadenomas or adenofibromas through a sequential and indolent process. These precursor lesions subsequently progress into serous borderline tumors (SBTs), which are characterized by invasive or non-invasive implants. SBTs progress to their full pathological potential over time and manifest as LGSOCs. Although the pathological development is generally considered to be sequential, rare instances exist where certain stages of the sequence may be skipped, leading to direct progression from a classic SBT to LGSOCs. Generally, LGSOCs are characterized by a higher likelihood of survival and are considered less aggressive than HGSOCs. However, they can experience instances of multiple recurrences and may exhibit reduced sensitivity to chemotherapy (4). Despite the slow growth pattern of LGSOCs, their tendency to be diagnosed at an advanced stage and resistance to standard systemic therapies ultimately contribute to the high fatality rate associated with this subtype. LGSOCs exhibit significant resistance to chemotherapy, and no established treatment is currently tailored for LGSOCs compared with HGSOCs. LGSOCs and HGSOCs exhibit different molecular and genetic features at the molecular level. Molecular biology investigations have identified the activation of the mitogen-activated protein kinase (MAPK) signaling pathway and the higher expression of estrogen receptors (ERs) (approximately 80.7%) and progestogen receptors (PRs) (approximately 54.4%) as factors involved in the pathogenesis of LGSOCs (5-7). HGSOCs are also characterized by widespread p53 mutations, elevated chromosomal instability, and germline alterations in the genes involved in homologous recombination repair, including BRCA1/2 (8). Numerous studies have reported a wide range of mutation frequencies in LGSOCs. Specifically, the prevalence of KRAS mutations in LGSOCs reportedly ranged from 16% to 44%, BRAF mutations from 2% to 20%, and NRAS mutations up to 26% in Western countries (6,7). Furthermore, alterations within the MAPK pathway have also been implicated in 60–82% of LGSOC cases (9,10). Among patients experiencing recurrences, KRAS hotspot mutations were the most common alterations, accounting for 33% of cases, followed by BRAF and NRAS alterations in 11% and 11%, respectively. Notably, these muta -Abstract Truncated-

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.

Abstract 6065: Patterns of Dysregulated Coding and Noncoding Gene Expression in High-Grade Serous Ovarian Carcinomas

A Clinically Applicable Molecular Classification for High-Grade Serous Ovarian Cancer Based on Hormone Receptor Expression.

What Influences the Long-Term Survival of Advanced High-Grade Serous Ovarian Cancer?

Expression of HLA-G in ovarian serous carcinoma and its clinical significance

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.

Prognostic And Therapeutic Factors For Low-Grade Serous Ovarian Carcinoma: A Multicentric, Retrospective Study Of The Turkish Society Of Gynaecologic Oncology

Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma

Advances in precision therapy of low-grade serous ovarian cancer: A review

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Gene Expression Profiles of Ovarian Low-Grade Serous Carcinoma Resemble Those of Fallopian Tube Epithelium.

[Expression of Sex Hormone Receptor in Gastric Cancer with Synchronous Ovarian Metastasis and Its Significance].

Article Evaluation of treatment strategies and prognostic factors of 135 patients with low-grade endometrial stromal sarcoma

Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma

Abstract 6279: Estrogen signaling in low-grade serous ovarian carcinoma

Current concept of low-grade serous ovarian carcinoma

Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma

Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas

A 2-Protein Signature Predicting Clinical Outcome In High-Grade Serous Ovarian Cancer

Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study